Russell Investments Group
CRNX

Russell Investments Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Russell Investments Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Sell
63,768
-44,107
-41% -$1.64M ﹤0.01% 1982
2026
Q1 		$3.92M Sell
107,875
-12,030
-10% -$537K ﹤0.01% 1495
2025
Q4 		$5.58M Sell
119,905
-29,077
-20% -$1.29M 0.01% 1257
2025
Q3 		$6.21M Sell
148,982
-7,401
-5% -$237K 0.01% 1182
2025
Q2 		$4.5M Sell
156,383
-9,955
-6% -$307K 0.01% 1279
2025
Q1 		$5.58M Buy
166,338
+132,138
+386% +$4.93M 0.01% 1103
2024
Q4 		$1.75M Sell
34,200
-43,501
-56% -$2.43M ﹤0.01% 1740
2024
Q3 		$3.97M Sell
77,701
-24,693
-24% -$1.27M 0.01% 1313
2024
Q2 		$4.59M Buy
102,394
+51,060
+99% +$2.36M 0.01% 1192
2024
Q1 		$2.4M Buy
51,334
+51,320
+366,571% +$2.01M ﹤0.01% 1552
2023
Q4 		$498 Hold
14
– – ﹤0.01% 3127
2023
Q3 		$416 Buy
+14
New +$288 ﹤0.01% 3424
2022
Q1 		– Sell
-843
Closed -$23K – 2782
2021
Q4 		$23K Sell
843
-82,261
-99% -$2.03M ﹤0.01% 2945
2021
Q3 		$1.75M Buy
+83,104
New +$1.74M ﹤0.01% 1910
2021
Q2 		– Sell
-14,001
Closed -$213K – 3221
2021
Q1 		$213K Buy
14,001
+4,019
+40% +$62.3K ﹤0.01% 2805
2020
Q4 		$140K Buy
9,982
+8,782
+732% +$122K ﹤0.01% 2825
2020
Q3 		$18K Sell
1,200
-4,400
-79% -$67.3K ﹤0.01% 3140
2020
Q2 		$98K Buy
+5,600
New +$95.5K ﹤0.01% 2886

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Russell Investments Group's CRNX Position: Q2 2026 in Review

Russell Investments Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 41% in Q2 2026, selling an estimated $1.64M and leaving 63,768 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1982.

Russell Investments Group first reported a position in CRNX in Q2 2020 and has held it in 18 quarters since. The position peaked at $6.21M in Q3 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Russell Investments Group held 63,768 shares of Crinetics Pharmaceuticals worth $2.39M as of Q2 2026.
  • Russell Investments Group sold 44,107 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.64M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1982 holding.
  • Russell Investments Group first reported a position in Crinetics Pharmaceuticals in Q2 2020 and has held it in 18 quarters since.
  • Russell Investments Group's Crinetics Pharmaceuticals position peaked at $6.21M in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.